Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI

Marex Group plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 262,000 shares of the company’s stock, valued at approximately $3,665,000. Marex Group plc owned about 0.18% of Denali Therapeutics as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Denali Therapeutics by 88.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock valued at $91,996,000 after acquiring an additional 3,184,042 shares during the period. SCS Capital Management LLC acquired a new stake in Denali Therapeutics in the first quarter worth about $2,692,000. TT International Asset Management LTD bought a new position in Denali Therapeutics in the 2nd quarter valued at about $909,000. Schroder Investment Management Group increased its stake in Denali Therapeutics by 32.5% during the 2nd quarter. Schroder Investment Management Group now owns 386,539 shares of the company’s stock valued at $5,408,000 after buying an additional 94,744 shares during the period. Finally, Norges Bank bought a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $55,224,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $17.98 on Friday. The company has a market capitalization of $2.64 billion, a PE ratio of -6.18 and a beta of 1.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The stock has a fifty day moving average of $17.04 and a 200-day moving average of $15.30. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same period last year, the business earned ($0.63) EPS. The firm’s revenue was up .0% compared to the same quarter last year. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analysts Set New Price Targets

DNLI has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a research note on Monday, November 17th. Wedbush lowered their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday. Morgan Stanley cut their price objective on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Finally, JPMorgan Chase & Co. raised their target price on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $32.58.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.